Aptinyx Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Aptinyx's estimated annual revenue is currently $6.7M per year.
- Aptinyx received $70.0M in venture funding in December 2017.
- Aptinyx's estimated revenue per employee is $156,279
- Aptinyx's total funding is $237.4M.
- Aptinyx has 43 Employees.
- Aptinyx grew their employee count by -23% last year.
- Aptinyx currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
|Heidolph North ...||$10.1M||65||16%||N/A||N/A|
What Is Aptinyx?
Welcome to our company page and thank you for your interest in Aptinyx Inc. Aptinyx is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need. At Aptinyx, we remain committed and responsive to our employees. We offer an engaging work environment, challenging work assignments, and competitive compensation and benefits. If you are interested in learning more, please visit our website at www.aptinyx.com.keywords:N/A
Number of Employees
Employee Growth %
|Sarah Torri||Executive Director|
|Nayereh Ghoreishi-Haack||Senior Research Manager|
|Tony Smolcich||Senior Director Information Technology||Email Available|
|Katie Hardek||Director, Human Resources|
|Amber Johnson||Associate Director of Finance||Email Available|
|Nick Smith||Sr. Director Of Corporate Development & Investor Relations||Email Available|
|Torsten Meldgaard||Chief Medical Officer|
|Kevin Newkirk||Associate Director, Program Management|
|Dan Watson||Sr. Clinical Operations Study Manager||Email Available|
|Andy Kidd||Chief Operating Officer|
EVANSTON, Ill., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing ...
Aptinyx Inc. (NASDAQ:APTX) Q2 2019 Results Earnings Conference Call August 12, 2019 8:00 AM ET. Company Participants. Nick Smith ...
On August 12, 2019, Aptinyx Inc., issued a press release announcing its financial results for the quarter ended June 30, 2019. A copy of the ...
|2016-05-10||$65.0M||A||New Leaf Venture Partners||Article|
|2017-12-19||$70.0M||B||Bain Capital Life Sciences||Article|
Aptinyx Executive Hires
|2017-12-08||Andy Kidd||Chief commercial officer||Article|
|2018-02-14||Ashish Khanna||Chief Financial Officer and Chief Business Officer||Article|
|2018-05-04||David Houck||Chief Development Officer||Article|